Infusion of Convalescent Plasma is Associated with Clinical Improvement in Critically Ill Patients with COVID-19: A Pilot Study



Título del documento: Infusion of Convalescent Plasma is Associated with Clinical Improvement in Critically Ill Patients with COVID-19: A Pilot Study
Revista: Revista de investigación clínica
Base de datos: PERIÓDICA
Número de sistema: 000453221
ISSN: 0034-8376
Autores: 1
1
1
2
3
4
4
5
5
3
1
1
1
1
Instituciones: 1Clínica Ruiz de Puebla, Centro de Hematología y Medicina Interna, Puebla. México
2Universidad Popular Autónoma del Estado de Puebla, Puebla. México
3Clínica Ruiz de Puebla, Laboratorios Ruiz, Puebla. México
4Hospital Puebla, Puebla. México
5Hospital Angeles Puebla, Puebla. México
Año:
Periodo: May-Jun
Volumen: 72
Número: 3
Paginación: 159-164
País: México
Idioma: Inglés
Tipo de documento: Artículo
Enfoque: Aplicado, descriptivo
Resumen en inglés Background: The ideal treatment of coronavirus disease (COVID)-19 has yet to be defined, but convalescent plasma (CoPla) has been successfully employed. Objective: The objective of the study was to study the safety and outcomes of the administration of CoPla to individuals with severe COVID-19 in an academic medical center. Methods: Ten patients were prospectively treated with plasma from COVID-19 convalescent donors. Results: Over 8 days, the sequential organ failure assessment score dropped significantly in all patients, from 3 to 1.5 (p = 0.014); the Kirby index (PaO2/FiO2) score increased from 124 to 255, (p < 0.0001), body temperature decreased significantly from 38.1 to 36.9°C (p = 0.0058), and ferritin levels also dropped significantly from 1736.6 to 1061.8 ng/ml (p = 0.0001). Chest X-rays improved in 7/10 cases and in 6/10, computerized tomography scans also revealed improvement of the lung injury. Decreases in C-reactive protein and D-dimer levels were also observed. Three of five patients on mechanical ventilation support could be extubated, nine were transferred to conventional hospital floors, and six were sent home; two patients died. The administration of CoPla had no side effects and the 24-day overall survival was 77%. Conclusions: Although other treatments were also administered to the patients and as a result data are difficult to interpret, it seems that the addition of CoPla improved pulmonary function
Disciplinas: Medicina
Palabras clave: Neumología,
Terapéutica y rehabilitación,
COVID-19,
SARS-CoV-2,
Infusiones,
Plasma
Keyword: Pneumology,
Therapeutics and rehabilitation,
COVID-19,
SARS-CoV-2,
Infusions,
Plasma
Texto completo: Texto completo (Ver HTML) Texto completo (Ver PDF)